澳门永利5335cc-Macau Software Store

CN
  • About the Company
  • Corporate Culture
  • Development History
  • Executives
  • Executives Video
  • Executives

    chairman

    Chairman—Wang Yutian

    Tenured Professor, University of British Columbia, Canada
    Heart Stroke Foundation of BC and Yukon
    Fellow, The Royal Society of Canada, 2006.
    International Researcher, Howard Hughes Medical Institute (HHMI), from 2001 to 2011
    Won the Canadian Innovation Award for Neurological and Psychopharmacological Research in 2017
    Overseas Review Expert of the Chinese Academy of Sciences
    Overseas Review Expert of the Natural Science Foundation of China
    Overseas Review Expert of the Changjiang Scholar Program of the Ministry of Education
    Overseas Expert & Advisory Committee Member of the Overseas Chinese Affairs Office of the State Council of the People's Republic of China
    Honorary Dean, Institute of Nerve Regeneration and Rehabilitation, Qingdao University
    Academician Wang Yutian is deeply involved in researching the mechanism behind major neurological diseases and the development of innovative drugs. In particular, he has achieved internationally leading results in the development of specific drugs for learning and memory disorders, cerebral stroke, drug addiction, Alzheimer's disease, depression, and other central nervous system diseases, and has acquired numerous internationally protected drug patents.
    Academician Wang Yutian has over a decade of experience in successfully managing and operating pharmaceutical enterprises. As one of the founders of Canada's NoNO Inc. Pharmaceutical Company, he shared data at the World Cerebral Stroke Conference in February 2020 on NA-1, a neuroprotective agent whose development he was involved in, which has completed an international multi-center Phase III clinical trial. NA-1 is the first neuroprotective agent to display protective functions for the brain in the past 50 years of global research. Moreover, he is also one of the founders of Canada's Primary Peptides Pharmaceutical Company, which authorized Suzhou Yabao Pharmaceutical Research and Development Co., Ltd. to conduct research on its SY-007 polypeptide project. The project has currently entered phase I clinical trial in China.

  • general manager

    General Manager—Yan Yi

    Bachelor of Science, Department of Biotechnology, School of Life Sciences, Peking University
    Master of Neuroscience, University of British Columbia, Faculty of Medicine, Canada
    Yan Yi’s is primarily involved in researching the mechanism of synaptic plasticity in the nervous system and the pathogenesis of related nervous system diseases. He is also deeply involved in researching the function of Akt in AMPA receptor trafficking and the resulting long-term potentiation (LTP), which can reveal the possible mechanism of Akt action and provide new targets and directions for treating related diseases and drug development. Furthermore, he has studied the mechanism of neuropeptides and their receptors in mediating synaptic plasticity and pain sensitivity in the central nervous system. His research results have brought light on the possible direction to further clarify the pain mechanism. Apart from years of scientific research experience, he has successful experience in running and managing companies, and in building teams and developing corporate culture. He has a strict and disciplined work style, and is highly capable and has excellent communication skills.

  • R&D director

    Director of Research and Development—Dong Mingxin

    Professor, Vice Dean of Institute of Nerve Regeneration and Rehabilitation, Qingdao University, Taishan Scholar
    Doctor of Pharmaceutical Chemistry, Academy of Military Medical Sciences
    Postdoctoral Fellow in Chemical Biology, University of Toronto, Canada
    Professor Dong Mingxin has been engaged in the research and development and production of small molecule and polypeptide drugs for over a decade in the Academy of Military Medical Sciences. He has successfully developed an antiviral small molecule drug which is undergoing phase I clinical trials. He has also completed the preclinical research of one small molecule and two polypeptide candidate drugs. He has published over 20 papers in international scientific journals and has over 10 national invention patents.

  • Project director

    Project Director—Geng Chuanrong

    Master of Pharmaceutical Chemistry, Fudan University
    Geng Chuanrong has previously worked in Shanghai Roche Pharmaceutical Co., Ltd. (Roche Shanghai Innovation Center), Shaoyuan Chemical Technology Co., Ltd., and Shandong Academy of Pharmaceutical Sciences. He has been engaged in innovative drug research and development and project management for a long time.
    His major research has been on dopamine (D3) and serotonin (5-HT1A) agonists and tyrosine kinase inhibitors in the central nervous system. He has developed several drug molecules with potential biological activities for the central nervous system through a series of processes, such as homologous modeling, kinetic analysis, virtual screening, etc., using computer-aided drug design based on crystal structure. Some of his works have been published in J. Chem. Inf. Model, Curr Pharm Biotech, and other renowned publications. He has also participated in major new drug innovation and development projects in Shandong Province in the field of tyrosine kinase inhibitors, and several of the projects have been funded by Shandong Provincial Science and Technology Department and Shandong Provincial Natural Science Foundation Committee.

  • Directors of HR & Administration

    Director of Human Resources Department—Sun Xiaochen

    National Level II Human Resource Administrator
    More than 10 years’ experience in human resource management and administration
    Sun Xiaochen is highly proficient in human resources and administrative management, and has exceptional corporate management skills. She has previously worked in Foxconn Technology Group, Qicai Construction Group, and other well-known domestic enterprises. She has in-depth understanding and practical experience in human resource management and administrative management in modern enterprises; and has rich experience in establishing a robust human resource management system for startups.

  • Business Consultant

    Business Consultant—Zhang Chaohui

    Doctor of Genetics, University of California, USA
    Postdoctoral Fellow in Biology, Stanford University, USA
    Visiting Professor, School of Business, Hong Kong University of Science and Technology
    As an entrepreneur and venture capitalist with rich experience in both the United States and China, Dr. Zhang Chaohui has experience working with top venture capital companies in Silicon Valley. He has founded three biotechnology companies in Silicon Valley, which have generated more than $200 million USD in returns for investors.

  • Medical consultant

    Medical Consultant—Wan Qi

    Professor of Qingdao University, National Outstanding Youth, Vice Minister of Medical Center, Dean of the Institute of Nerve Regeneration and Rehabilitation
    Vice Minister of Medical Center, Vice Dean of Medical Research Institute, Vice Minister of Postgraduate Education and International Exchange of Wuhan University
    Tenured Professor, University of Nevada, USA
    Senior Scientist, University of Toronto, Canada
    Wan Qi is the winner of the Canadian HSF and MRC Fellowship Awards and Canadian Research Foundation Awards. He has also published his works in Nature, Nature Neuroscience, Nature Medicine and other renowned publications, and has been invited to publish review articles in Trends in Neuroscience.

  • Copyright © 2020 Qingdao Primedicine Pharmaceutical Technology Co., Ltd. All right reserved

    XML 地图